NASDAQ:XFOR

X4 Pharmaceuticals - XFOR Stock Forecast, Price & News

$1.04

0.00 (0.00%)

(As of 02/3/2023 12:00 AM ET)

Add

Compare

Today's Range: $1.01
▼
$1.07
50-Day Range: $0.69
▼
$1.85
52-Week Range: $0.65
▼
$2.41

Volume: 658,543 shs
Average Volume: 768,538 shs
Market Capitalization: $72.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.86

Institutional Ownership

X4 Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 559.3% Upside
$6.86 Price Target
Short Interest: Healthy
1.81% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.85
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.43) to ($0.83) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.74 out of 5 stars

Medical Sector

38th out of 1,028 stocks

Biological Products, Except Diagnostic Industry

8th out of 168 stocks

3.5

Analyst's Opinion

Consensus Rating
X4 Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.86, X4 Pharmaceuticals has a forecasted upside of 559.3% from its current price of $1.04.
Amount of Analyst Coverage
X4 Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.81% of the outstanding shares of X4 Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
X4 Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in X4 Pharmaceuticals has recently decreased by 20.89%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
X4 Pharmaceuticals does not currently pay a dividend.
Dividend Growth
X4 Pharmaceuticals does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
X4 Pharmaceuticals has received a 71.51% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for mental health" and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for X4 Pharmaceuticals is -0.85.

2.4

News and Social Media Coverage

News Sentiment
X4 Pharmaceuticals has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for X4 Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 9 people have searched for XFOR on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added X4 Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, X4 Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
95.90% of the stock of X4 Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
56.46% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($1.43) to ($0.83) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of X4 Pharmaceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of X4 Pharmaceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
X4 Pharmaceuticals has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About X4 Pharmaceuticals (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XFOR Stock News Headlines

January 31, 2023 | finance.yahoo.com

What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock

January 29, 2023 | americanbankingnews.com

Short Interest in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Declines By 20.9%

February 5, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.

January 21, 2023 | forbes.com

X4 Pharmaceuticals

January 14, 2023 | seekingalpha.com

XFOR X4 Pharmaceuticals, Inc.

December 12, 2022 | finance.yahoo.com

X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia

December 7, 2022 | finance.yahoo.com

X4 Pharmaceuticals Prices $65.0 Million Public Offering

November 30, 2022 | finance.yahoo.com

X4 Pharmaceuticals Shares Tumble After Phase 3 Data From Rare Immune Deficiency Candidate

February 5, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

November 30, 2022 | seekingalpha.com

X4 Pharma sheds 16% even as rare disease therapy meets main goal in Phase 3 trial

November 30, 2022 | finance.yahoo.com

X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome

November 17, 2022 | finance.yahoo.com

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) most popular amongst individual investors who own 40% of the shares, institutions hold 34%

November 8, 2022 | finance.yahoo.com

X4 Pharmaceuticals to Present at Stifel Healthcare Conference

November 5, 2022 | seekingalpha.com

X4 Pharmaceuticals, Inc. (XFOR) Q3 2022 Earnings Call Transcript

November 3, 2022 | msn.com

X4 Pharmaceuticals: Q3 Earnings Insights

November 3, 2022 | finance.yahoo.com

X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

October 26, 2022 | finance.yahoo.com

X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

October 20, 2022 | finance.yahoo.com

X4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022

October 5, 2022 | finance.yahoo.com

X4 Pharma Highlights New Data Supporting Mavorixafor's Broad Potential In Chronic Neutropenia

September 27, 2022 | seekingalpha.com

X4 stock rises 10% as mavorixafor shows promise in trial for white blood cell disorder

September 27, 2022 | finance.yahoo.com

X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)

August 18, 2022 | finance.yahoo.com

All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy

August 8, 2022 | finance.yahoo.com

X4 Pharmaceuticals to Present at Canaccord Genuity’s 42nd Annual Growth Conference

August 7, 2022 | seekingalpha.com

X4 Pharmaceuticals, Inc.'s (XFOR) CEO Dr. Paula Ragan on Q2 2022 Results - Earnings Call Transcript

August 7, 2022 | seekingalpha.com

X4 Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation

August 4, 2022 | finance.yahoo.com

X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 4, 2022 | finance.yahoo.com

X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XFOR Company Calendar

Last Earnings: 11/04/2021
Today: 2/05/2023
Next Earnings (Estimated): 3/16/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:XFOR
CUSIP: N/A
CIK: 1501697
Web: www.x4pharma.com
Phone: (857) 529-8300
Fax: N/A
Employees: 83
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.86
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +559.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.82)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-88,700,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -184.37%
Return on Assets: -92.38%

Debt

Debt-to-Equity Ratio: 0.30
Current Ratio: 2.99
Quick Ratio: 2.99

Sales & Book Value

Annual Sales: $3 million
Price / Sales: 24.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.61 per share
Price / Book: 0.40

Miscellaneous

Outstanding Shares: 69,240,000
Free Float: 2,839,000
Market Cap: $72.01 million
Optionable: Not Optionable
Beta: 0.50

Key Executives

Paula S. Ragan
President, Chief Executive Officer & Director

Mary DiBiase
Chief Operating Officer

Adam S. Mostafa
Chief Financial Officer & Treasurer

Murray W. Stewart
Independent Director & Chief Medical Officer

Art Taveras
Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XFOR Stock - Frequently Asked Questions

Should I buy or sell X4 Pharmaceuticals stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XFOR shares.
View XFOR analyst ratings or view top-rated stocks.
What is X4 Pharmaceuticals' stock price forecast for 2023?: 5 brokers have issued 12-month price objectives for X4 Pharmaceuticals' stock. Their XFOR share price forecasts range from $3.00 to $10.00. On average, they anticipate the company's stock price to reach $6.86 in the next twelve months. This suggests a possible upside of 559.3% from the stock's current price.
View analysts price targets for XFOR or view top-rated stocks among Wall Street analysts.
How have XFOR shares performed in 2023?: X4 Pharmaceuticals' stock was trading at $0.9930 at the start of the year. Since then, XFOR stock has increased by 4.7% and is now trading at $1.04.
View the best growth stocks for 2023 here.
Are investors shorting X4 Pharmaceuticals?: X4 Pharmaceuticals saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 1,250,000 shares, a decrease of 20.9% from the December 31st total of 1,580,000 shares. Based on an average trading volume of 1,270,000 shares, the short-interest ratio is presently 1.0 days.
View X4 Pharmaceuticals' Short Interest.
When is X4 Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our XFOR earnings forecast.
How were X4 Pharmaceuticals' earnings last quarter?: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.04. During the same quarter last year, the company earned ($0.87) EPS.

What other stocks do shareholders of X4 Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX).
What is X4 Pharmaceuticals' stock symbol?: X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR."
Who are X4 Pharmaceuticals' major shareholders?: X4 Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adam S Mostafa, Adam S Mostafa, Derek M Meisner, Derek M Meisner, Paula Ragan and Renato Skerlj.
View institutional ownership trends.
How do I buy shares of X4 Pharmaceuticals?: Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is X4 Pharmaceuticals' stock price today?: One share of XFOR stock can currently be purchased for approximately $1.04.
How much money does X4 Pharmaceuticals make?: X4 Pharmaceuticals (NASDAQ:XFOR) has a market capitalization of $72.01 million and generates $3 million in revenue each year. The company earns $-88,700,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis.
How can I contact X4 Pharmaceuticals?: X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The official website for the company is www.x4pharma.com. The company can be reached via phone at (857) 529-8300 or via email at ir@arsanis.com.

This page (NASDAQ:XFOR) was last updated on 2/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

X4 Pharmaceuticals - XFOR Stock Forecast, Price & News

X4 Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About X4 Pharmaceuticals (NASDAQ:XFOR) Stock

XFOR Stock News Headlines

XFOR Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

XFOR Stock - Frequently Asked Questions

Overall MarketRank^™